Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00311096 | Thyroid | PTC | microtubule polymerization or depolymerization | 57/5968 | 122/18723 | 4.19e-04 | 2.81e-03 | 57 |
GO:00613873 | Thyroid | PTC | regulation of extent of cell growth | 52/5968 | 110/18723 | 5.20e-04 | 3.37e-03 | 52 |
GO:00063385 | Thyroid | PTC | chromatin remodeling | 106/5968 | 255/18723 | 6.56e-04 | 4.13e-03 | 106 |
GO:003210316 | Thyroid | PTC | positive regulation of response to external stimulus | 167/5968 | 427/18723 | 8.31e-04 | 5.13e-03 | 167 |
GO:00022186 | Thyroid | PTC | activation of innate immune response | 28/5968 | 52/18723 | 8.33e-04 | 5.13e-03 | 28 |
GO:00303087 | Thyroid | PTC | negative regulation of cell growth | 80/5968 | 188/18723 | 1.28e-03 | 7.31e-03 | 80 |
GO:00305209 | Thyroid | PTC | intracellular estrogen receptor signaling pathway | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
GO:000975519 | Thyroid | PTC | hormone-mediated signaling pathway | 80/5968 | 190/18723 | 1.84e-03 | 9.91e-03 | 80 |
GO:001481212 | Thyroid | PTC | muscle cell migration | 50/5968 | 110/18723 | 1.93e-03 | 1.04e-02 | 50 |
GO:006053719 | Thyroid | PTC | muscle tissue development | 156/5968 | 403/18723 | 1.98e-03 | 1.06e-02 | 156 |
GO:003030718 | Thyroid | PTC | positive regulation of cell growth | 71/5968 | 166/18723 | 1.98e-03 | 1.06e-02 | 71 |
GO:00434057 | Thyroid | PTC | regulation of MAP kinase activity | 75/5968 | 177/18723 | 2.04e-03 | 1.09e-02 | 75 |
GO:00331356 | Thyroid | PTC | regulation of peptidyl-serine phosphorylation | 62/5968 | 144/18723 | 3.05e-03 | 1.50e-02 | 62 |
GO:00450887 | Thyroid | PTC | regulation of innate immune response | 89/5968 | 218/18723 | 3.16e-03 | 1.55e-02 | 89 |
GO:000176316 | Thyroid | PTC | morphogenesis of a branching structure | 81/5968 | 196/18723 | 3.20e-03 | 1.57e-02 | 81 |
GO:00149095 | Thyroid | PTC | smooth muscle cell migration | 44/5968 | 97/18723 | 3.65e-03 | 1.76e-02 | 44 |
GO:00331464 | Thyroid | PTC | regulation of intracellular estrogen receptor signaling pathway | 19/5968 | 35/18723 | 4.94e-03 | 2.29e-02 | 19 |
GO:004863810 | Thyroid | PTC | regulation of developmental growth | 127/5968 | 330/18723 | 6.09e-03 | 2.71e-02 | 127 |
GO:00480123 | Thyroid | PTC | hepatocyte growth factor receptor signaling pathway | 9/5968 | 13/18723 | 6.33e-03 | 2.79e-02 | 9 |
GO:00107624 | Thyroid | PTC | regulation of fibroblast migration | 19/5968 | 36/18723 | 7.38e-03 | 3.16e-02 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAK1 | SNV | Missense_Mutation | | c.184N>A | p.Asp62Asn | p.D62N | Q13153 | protein_coding | tolerated(0.38) | benign(0.033) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PAK1 | SNV | Missense_Mutation | | c.1114G>A | p.Glu372Lys | p.E372K | Q13153 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PAK1 | SNV | Missense_Mutation | | c.229N>A | p.Leu77Ile | p.L77I | Q13153 | protein_coding | tolerated(0.41) | benign(0.236) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1593N>C | p.Met531Ile | p.M531I | Q13153 | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
PAK1 | SNV | Missense_Mutation | | c.113N>G | p.Ser38Cys | p.S38C | Q13153 | protein_coding | tolerated(0.17) | probably_damaging(0.917) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | insertion | Nonsense_Mutation | novel | c.226_227insGTGCACATGTATATATATGTATGCAAGAATTTTAATTTT | p.Ile75_Ser76insCysAlaHisValTyrIleCysMetGlnGluPheTerPhe | p.I75_S76insCAHVYICMQEF*F | Q13153 | protein_coding | | | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PAK1 | SNV | Missense_Mutation | | c.1532C>T | p.Ser511Leu | p.S511L | Q13153 | protein_coding | deleterious(0) | benign(0.135) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.946A>G | p.Ile316Val | p.I316V | Q13153 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | novel | c.80N>A | p.Gly27Asp | p.G27D | Q13153 | protein_coding | deleterious_low_confidence(0.04) | benign(0.02) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAK1 | SNV | Missense_Mutation | | c.95N>A | p.Gly32Glu | p.G32E | Q13153 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | AZD-1152-HQPA | AZD-1152-HQPA | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TOZASERTIB | TOZASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | allosteric modulator | 310264717 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | MLN-8054 | MLN-8054 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 310264719 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565861 | | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | RG-1530 | RG-1530 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PF-562271 | PF-00562271 | |
5058 | PAK1 | KINASE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TAE-684 | TAE-684 | |